Chalitpon Na Nakorn
Overview
Explore the profile of Chalitpon Na Nakorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vanwong N, Tipnoppanon S, Na Nakorn C, Srisawasdi P, Rodcharoen P, Medhasi S, et al.
Pharmgenomics Pers Med
. 2022 Feb;
15:119-130.
PMID: 35210819
Purpose: Statins are increasingly widely used in the primary and secondary prevention of cardiovascular disease. However, there is an inter-individual variation in statin response among patients. The study aims to...
2.
Vanwong N, Sukasem C, Unaharassamee W, Jiratjintana N, Na Nakorn C, Hongkaew Y, et al.
J Pers Med
. 2021 Oct;
11(10).
PMID: 34683084
Background: Patients with psychotic disorders who receive atypical antipsychotic drugs often develop metabolic abnormalities. The sterol regulatory element-binding factor 2 (SREBF2) gene and insulin-induced gene (INSIG) have important roles in...
3.
Vanwong N, Puangpetch A, Unaharassamee W, Jiratjintana N, Na Nakorn C, Hongkaew Y, et al.
Pharmacoepidemiol Drug Saf
. 2021 Mar;
30(6):806-813.
PMID: 33683783
Background: The use of Atypical antipsychotics (AAPs) is related to metabolic disturbances, which put psychiatric patients at risk for cardiovascular morbidity and mortality. Evidence is emerging of genetic risk factors....
4.
Srisawasdi P, Rodcharoen P, Vanavanan S, Chittamma A, Sukasem C, Na Nakorn C, et al.
Pharmgenomics Pers Med
. 2021 Jan;
14:1-13.
PMID: 33447072
Objective: Patients treated with statins for dyslipidemia may still have a residual risk of atherosclerotic cardiovascular disease (ASCVD). To determine whether genetic variants in the cholesteryl ester transport protein (CETP),...
5.
Na Nakorn C, Waisayarat J, Dejthevaporn C, Srisawasdi P, Wongwaisayawan S, Sukasem C
Front Pharmacol
. 2020 Jun;
11:728.
PMID: 32581780
Aim: To investigate the variations and the frequencies of the gene in the Thai population. Methods: Collected samples were categorized into five regions of Thailand. DNA samples were genotyped for...
6.
Satapornpong P, Jinda P, Jantararoungtong T, Koomdee N, Chaichan C, Pratoomwun J, et al.
Front Pharmacol
. 2020 Mar;
11:78.
PMID: 32180714
Human leukocyte antigen (HLA) class I and II are known to have association with severe cutaneous adverse reactions (SCARs) when exposing to certain drug treatment. Due to genetic differences at...
7.
Puangpetch A, Srisawasdi P, Unaharassamee W, Jiratjintana N, Vanavanan S, Punprasit S, et al.
Pharmgenomics Pers Med
. 2019 Sep;
12:155-166.
PMID: 31496784
Objective: To determine whether genetic polymorphisms related to pharmacodynamics with metabolic adverse effects, namely leptin promoter () rs7799039, leptin receptor rs1137101, dopamine D2 rs4436578, serotonin 5-HT2A rs6313, and serotonin 5-HT2C...